Drugging WRN: Clinical Proof-of-Concept Established Available to Purchase

WRN inhibitor development is burgeoning, with four candidates now in phase I trials.  First-in-human findings on one, RO7589831, indicate that the drug is safe, well tolerated, and shows promising early efficacy. Another candidate, GSK4418959, appears capable of inducing regressions even in tumors with acquired RO7589831 resistance, albeit the data are only preclinical so far.